We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The solution offers advanced functionality such as femoral and radial access, ability to remove stent and reset lesion for repeatable training, angle assistance to enhance 3D understanding, a large selection of anatomical variations including post CABG ca
Johnson & Johnson's Opsumit (macitentan) has shown significant improvement in pulmonary vascular resistance (PVR) in patients with portopulmonary hypertension (PoPH) after 24 weeks, in data published in The Lancet Respiratory Medicine.